Vazobral

General characteristics. Structure:

Active components: дигидроэргокриптин α-мезилат 1,0 mg; caffeine of 10,0 mg

Excipients: citric acid monohydrate, ethanol, glycerin, water.

Pharmacological properties:

The combined drug. α-Digidroergokriptin – dihydrogenated derivative an ergot, blocks α1 and α2 adrenoceptors. Has dofaminergichesky, serotonergic effect, reduces aggregation of thrombocytes and erythrocytes, reduces permeability of a vascular wall, increases quantity of the functioning capillaries, improves blood circulation and processes of metabolism in a brain, increases resistance of tissues of brain to a hypoxia.
Caffeine possesses psychogogic and analeptical action, strengthens processes of excitement in a cerebral cortex – increases intellectual and physical effeciency, reduces fatigue and drowsiness, increases reflex irritability of a spinal cord, excites the respiratory and vasomotor centers, has diuretic effect.

Pharmacokinetics. At oral administration, absorption of a digidroergokriptin accelerates in the presence of caffeine (time of achievement of the maximum concentration in a blood plasma 0,5 hours).
The maximum concentration after intake of 8 mg of a α-digidroergokriptin makes 227 pg/ml, and semi-removal time – less than 2 hours.

Indications to use:

- the decrease in intellectual activity, disturbance of attention and memory, disturbance of orientation in space caused by age changes;
- cerebrovascular insufficiency (including owing to cerebral atherosclerosis);
- effects of disturbance of cerebral circulation;
- prevention of migraine;
- vestibular and labyrinth disturbances (dizziness, sonitus, gipoakuziya) of ischemic genesis;
- Menyer's disease;
- retinopathy (diabetic and hypertensive);
- disturbances of peripheric arterial circulation (syndrome and Raynaud's disease);
- venous insufficiency.

Route of administration and doses:

Inside (during food, with a small amount of liquid) on 2-4 ml (1-2 dosing the syringe) 2 times a day. Duration of a course of treatment 2-3 months, if necessary it is possible to treat 1-2 times a year.

Features of use:

Vazobral has vasodilating effect, without influencing system arterial pressure. Vazobral's appointment the patient with arterial hypertension does not exclude need use of anti-hypertensive means. The caffeine which is contained in drug can cause a sleep disorder, tachycardia.

Side effects:

From digestive tract: nausea, a gastralgia, dyspepsia, at these manifestations drug withdrawal is not required. Seldom (no more than 1% of cases) – dizziness, excitement, a headache. Very seldom (no more than 0,1% of cases) allergic reactions, tachycardia, hypotension are possible.

Interaction with other medicines:

At co-administration of Vazobral and hypotensive drugs development of arterial hypotonia is possible. Caffeine weakens action of hypnagogues.

Contraindications:

The increased individual sensitivity to drug components.

Pregnancy and period of a lactation.
There are no clinical data on Vazobral's use during pregnancy and feeding by a breast. Use of drug during breastfeeding can lead to reduction of a lactation.

Overdose:

Symptoms – strengthening of expressiveness of side effects.
Symptomatic treatment.

Storage conditions:

At a temperature of 15-25 °C, in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

On 50 ml in a bottle of dark glass together with the application instruction and the dosing syringe in a cardboard box.